Advantage India due to the Biosecure Act
Kaushik Gopal Bhattacharaya, Head - Territory Sales Support (Global), Syngene International highlights how outbound leads in the…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Syngene
Syngene secures silver rating in EcoVadis sustainability index, ranking in top 15% of assessed…
82% renewable energy and zero waste to landfill across all campuses
Veeda Board appoints Dr Mahesh Bhalgat as Group CEO
Prior to joining Veeda, he was the COO for Syngene International (Biocon Group Company)
Syngene to acquire multi-modal facility from Stelis Biopharma
Adds 20,000 liters of installed biologics drug substance manufacturing capacity, with scope for further expansion, and a high…
Biocon Academy conducts graduation ceremony for 185 students across four programs
Over 900 students have received academic learning and industrial training on applied aspects of various biotech-related…
Syngene reports strong third quarter results
Revenue up to Rs 803 crore, PAT up to Rs 110 crores
Syngene reports revenue from operations up eight per cent in Q1
The first quarter results were against a strong quarter last year due to sales of COVID treatment, Remdesivir
Orphan drug development remains a specialised segment with limited players
Recently, Syngene International was involved in the development of a drug for a rare disease that affects children. Dr Mahesh…
Syngene reports 10 per cent growth in revenue from operations
Growth in profit after tax was impacted by a lower effective tax rate in the third quarter last year due to a tax reversal and…
The future CRO/CDMO will offer end-to-end solutions and operate as a large pharma or biotech company
Dr Mahesh Bhalgat, COO, Syngene talks about his company's outlook, investments and capacity expansion, as well as Syngene's plans…